08:04 AM EST, 02/13/2025 (MT Newswires) -- Microbix Biosystems ( MBXBF ) said Thursday that its net income and revenue dropped in the first quarter of its fiscal 2025.

The company, which provides proprietary biological products for human health, reported a net and comprehensive income of $856,962 for the quarter ended Dec. 31, sliding from $2.5 million a year ago when earnings were driven by non-recurring Kinlytic licensing revenues.

Microbix booked revenue of $6 million, falling from $8.4 million, although the company noted a 118% increase in antigen revenues due to continuing strong demand.

The company said it aims to continue driving sales growth across all of its business lines and work to keep improving percentage gross margins while delivering bottom-line results.

Microbix said it expects to generate "meaningful year-over-year growth" in revenues for fiscal 2025.